The Biotech Investor's Bible. This item is unavailable.
Language: English
Published by Wiley, 2001
- Hardcover
- Used

Seller: WeBuyBooks, Rossendale, LANCS, United KingdomWeBuyBooks
AbeBooks seller since November 14, 2005
Condition: Used - Very good
£ 2.74
Item description from seller
Most items will be dispatched the same or the next working day. A copy that has been read, but is in excellent condition. Pages are intact and not marred by notes or highlighting. The spine remains undamaged.
Seller Inventory # rev5239176033
- Title
- The Biotech Investor's Bible
- Author
- Wolff, George
- Publisher
- Wiley
- Publication year
- 2001
- Condition
- Very Good
- Binding
- Hardcover
- Language
- English
- ISBN 10
- 0471412791
- ISBN 13
- 9780471412793
- Item weight
- 220 grams
A one-stop source for investing in biotech-with detailed coverage of the science, the business, the players, and the strategies for one of today's most promising (and volatile) industries
To invest in biotech is to invest in the future, and as such, investors need to learn the nuances of the science they're putting their money on. The core asset of biotech companies is knowledge, and sound investment decisions are impossible without an understanding of this complex science. That's where The Biotech Investor's Bible fits in. This much-needed, one-of-a-kind resource simplifies the complex science surrounding the business of biotech and clarifies subtle distinctions within the context of their financial repercussions. The book explains the basics of genetics, patents, and therapies; and teaches investors how to value biotech companies and their state-of-the art products and technology. The Biotech Investor's Bible offers an informative summary of the relatively short history of the industry and provides a comprehensive review of various industry sectors.
"Synopsis" may belong to another edition of this title.
About the Author
GEORGE WOLFF is an award-winning journalist and, currently, a private business consultant to several firms in the investment industry. He has assessed and reported on more than 200 biotechnology companies for his clientele, issuing a number of valuable white papers charting the emergence of biotechnology. Previously, as a journalist, Wolff worked internationally covering the onset of the AIDS epidemic, the emergence of recombinant DNA technology, and the extraordinary stock market events of the previous twenty years. Wolff can be contacted through his web site, BioWolff.com.
"About the title" may belong to another edition of this title.